Next Generation Sequencing Market to Reach $46.5 Billion by 2035, Growing at 18.9% CAGR | Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies

The global next generation sequencing market, valued at USD 8.6 billion in 2025 and projected to reach USD 9.8 billion in 2026, will expand to USD 46.5 billion by 2035, growing at a compounded annual growth rate of 18.9% across the forecast period. This growth reflects accelerating adoption of NGS technologies across oncology diagnostics, genetic disorder screening, and precision medicine programs spanning academic research, hospital networks, and pharmaceutical development.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/next-generation-sequencing/request-sample.html

Market Overview
Next generation sequencing has become the foundational technology for understanding genetic variation at scale. By enabling rapid sequencing of entire genomes, exomes, or targeted regions, NGS gives researchers and clinicians the ability to identify disease-causing mutations, track pathogen evolution, guide cell therapy design, and pinpoint actionable biomarkers. What once required months and millions of dollars can now be completed in hours at a fraction of the cost, making the technology accessible to a far broader range of institutional and clinical users.

The urgency behind NGS adoption is not abstract. According to the Centers for Disease Control and Prevention, nearly six in ten Americans live with at least one chronic disease, and global cancer incidence continues to rise, with the American Cancer Society projecting more than two million new cancer cases in the United States alone in 2024. These figures are pushing pharmaceutical companies, hospital systems, and national health programs to invest directly in sequencing infrastructure and outsourced NGS services.

Government-backed genome initiatives are also shaping market direction. In January 2025, the Government of India, in collaboration with Tata Memorial Hospital, launched the Indian Genomic Dataset and IBDC portals, designed to empower global genomic research. Oxford Nanopore Technologies announced a partnership with the UK government in November 2024 to expand genomics-based translational research within the National Health Service. These programs signal that NGS is no longer confined to specialist research laboratories; it is becoming embedded in national health infrastructure.

Key Growth Drivers
Rising burden of oncological and genetic disorders. Cancer and hereditary disease are the primary end-use cases driving NGS adoption. Oncological disorders represent approximately 50% of the current NGS therapeutic area market, valued at USD 4.3 billion in 2026. NGS-guided therapies have demonstrated strong disease control rates in clinical trials, which continues to bring more patients and sponsors into active studies. More than 920 clinical trials related to NGS have been registered over the past five years, with approximately 55% actively recruiting patients at present.

Surge in clinical trial activity and pharmaceutical investment. Biotechnology and pharmaceutical companies are directing substantial resources toward evaluating the diagnostic and therapeutic potential of NGS platforms. Psomagen, partnering with the Global Parkinson's Genetics Program in March 2024, committed to whole genome sequencing of nearly 80,000 patients to support the development of therapeutic strategies for Parkinson's disease. Thermo Fisher Scientific and Pfizer joined forces in May 2023 to expand localized access to NGS-based testing for cancer patients across global markets.

Technological advancement in sequencing platforms. Platform providers are competing aggressively on throughput, accuracy, and cost-per-genome. Key recent introductions include Thermo Fisher's Ion Torrent Genexus Dx Integrated Sequencer, Oxford Nanopore's PromethION, Illumina's iSeq 100, and Ultima Genomics' UG 100, which Inocras began offering alongside bioinformatics services in August 2024. Since 2020, more than 3,060 patents focused on NGS have been granted or filed, reflecting the pace of innovation across the sector.
Expansion of portable and point-of-care sequencing. Developers are pushing toward handheld sequencing devices that reduce cost, simplify workflows, and enable real-time analysis outside central laboratory settings. Oxford Nanopore's MinION, capable of reading DNA and RNA fragments up to 4 megabases, represents the current standard for portable NGS. Growing demand for field-deployable and clinic-ready solutions opens a significant new commercial channel beyond the traditional academic and hospital customer base.

Growth in non-invasive prenatal testing. The increasing clinical preference for non-invasive prenatal testing (NIPT) is driving demand for cell-free DNA sequencing kits tailored to detect chromosomal abnormalities, including Down syndrome, cystic fibrosis, and sickle cell anemia, at early stages of pregnancy. This application area benefits from both clinical validation and the growing consumer expectation that genomic screening should be accessible during routine prenatal care.

Market Segmentation
By component type, consumables account for 67% of total NGS market revenue, driven by high recurring demand from research applications, and this segment will maintain its dominance through 2035 with a projected CAGR of 18.7%. Sequencing by synthesis technology, led by Illumina's platforms, holds an 82% share within the technology segment, though nanopore sequencing is the fastest-growing technology category at a CAGR of 20.5%, reflecting growing interest in long-read sequencing and portable applications. By NGS technique, targeted sequencing holds the largest share at 45%, while whole genome and whole exome sequencing is set to grow at 19.5% CAGR, the highest among technique segments.

Clinical applications currently account for 57% of market revenue by application area and will grow at a CAGR of 21.1%, reflecting the accelerating integration of NGS into diagnostic workflows at hospitals and specialized clinics. Academic and research institutes represent the largest end-user segment at 45% market share, driven by oncology research and personalized medicine programs. The hospitals and clinics segment, however, carries the fastest growth trajectory at 21.7% CAGR, as NGS moves from research settings into routine clinical practice. Within therapeutic areas, oncological disorders hold a 50% market share; the "other therapeutic areas" category is expected to outpace all others at 26.6% CAGR.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/next-generation-sequencing/request-quote.html

Regional Insights
North America commands 51% of the global NGS market, a position that will persist through 2035. The region benefits from a mature network of technology manufacturers, supportive regulatory frameworks for genome sequencing, advanced hospital infrastructure, and a concentrated focus on oncology precision medicine. These structural advantages make it the primary commercial battleground for platform vendors and service providers alike.

Europe follows with a projected 23% market share. Investments in national genomics programs, including the UK's NHS partnership with Oxford Nanopore, and the expansion of multiomics laboratory networks by companies such as Azenta, which opened a new GENEWIZ genomics laboratory in Oxford in May 2024, are reinforcing the region's research and clinical capacity.

Asia-Pacific is the fastest-growing regional market, with a projected CAGR of 20.6% through 2035. Government support for clinical research, rapid improvement in healthcare infrastructure, and a rising volume of industrial partnerships are driving this growth. Illumina and Thermo Fisher Scientific are both deepening their partnerships with Asian industrial partners to support product expansion in this region. India's national genomics data initiative, launched in early 2025, adds further institutional momentum to the region's trajectory.

Competitive Landscape
Key players profiled in the next generation sequencing industry include Admera Health, Applied Biological Materials, BGI Genomics, CD Genomics, DNA Link, Eurofins Genomics, Gene by Gene, GENEWIZ, Illumina, MedGenome, MGI Tech, Novogene, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Psomagen, Thermo Fisher Scientific, Veritas, and Xcelris Labs.

The technology segment is concentrated around a small number of platform developers, with Illumina holding dominant share through its sequencing by synthesis systems. However, Oxford Nanopore Technologies and PacBio are applying sustained competitive pressure through long-read sequencing platforms, and newer entrants like Ultima Genomics are targeting the cost frontier. The service provider segment is considerably more fragmented, featuring nearly 90 companies across size tiers, with 92% offering whole genome sequencing and 48% providing all three major sequencing service types. Competition in services centers on turnaround time, data quality, bioinformatics integration, and geographic reach rather than technology differentiation alone.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/next-generation-sequencing/290.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.